# **PROVIDER OUICK POINTS** PROVIDER INFORMATION



August 12, 2020

## MHCP Pharmacy Benefit Update: Pharmacy Benefit Exclusion for Phesgo<sup>™</sup>, Uplizna<sup>™</sup>, and Zepzelca<sup>™</sup>

Effective **July 26, 2020**, the drugs listed in the table below will be excluded from pharmacy benefit coverage due to clinician-administered route of administration and may be available for medical benefit coverage for subscribers who are eligible.

#### **Drug Name and Strength**

Phesgo<sup>TM</sup> (pertuzumab, trastuzumab, and hyaluronidase) injection 60 mg/60 mg/2000 unit/mL, 80 mg/40 mg/2000 units/mL

Uplizna<sup>TM</sup> (inebilizumab-cdon) intravenous solution 10mg/mL

Zepzelca<sup>TM</sup> (lurbinectedin) intravenous solution 4mg

#### **Products Impacted**

This applies to the following Minnesota Health Care Programs.

- Families and Children [formerly known as Prepaid Medical Assistance Program (PMAP)]
- MinnesotaCare (MNCare)
- Minnesota Senior Care Plus (MSC+)

### **Questions?**

If you have questions for a member enrolled in a Minnesota Health Care Programs (MHCP) plan, please contact provider services at **1-866-518-8448**. Please contact provider services at **(651) 662-5200** or **1-800-262-0820** for all other questions.